nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

01.01.2023 | Original article

Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers

verfasst von: Panagiotis Theofilis, Aikaterini Vordoni, Vasilis Tsimihodimos, Rigas G. Kalaitzidis

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Patients with arterial hypertension frequently present with comorbidities that are associated with increased cardiorenal risk, such as metabolic dysfunction-associated fatty liver disease (MAFLD).

Aims

Our study aimed to assess the prevalence and the association of MAFLD with cardiorenal risk markers in newly diagnosed, treatment-naïve hypertensive patients.

Methods

We recruited 281 individuals with new-onset hypertension who were not prescribed any medication. Medical history, clinical examination findings, and laboratory test results were recorded. Liver steatosis was assessed through fatty liver index (FLI) calculation. Patients with FLI ≥ 60 together with one main metabolic abnormality (type 2 diabetes mellitus or overweight/obesity) or at least two metabolic risk abnormalities (increased waist circumference, blood pressure, plasma triglycerides, presence of prediabetes or insulin resistance, decreased plasma high-density lipoprotein) fulfilled the diagnostic criteria for MAFLD.

Results

The prevalence of MAFLD in our study population was 28.7%. Individuals with MAFLD were more frequently male and had increased body mass index. Systolic, diastolic, and pulse pressure values were significantly higher in this group of patients. Moreover, lipid, renal, glucose, and inflammatory markers were considerably deranged in patients with MAFLD. After multivariate regression analysis, uric acid, ferritin, and apoE emerged as independent predictors of MAFLD. Area under receiver operating characteristics curve revealed that uric acid had the greatest diagnostic accuracy, with the ideal cutoff being ≥ 5.2 mg/dl (sensitivity: 77.6%, specificity: 76.3%).

Conclusion

MAFLD represents a common comorbidity in hypertensive patients and is associated with markers of cardiorenal risk. Uric acid may be indicative of MAFLD in particular.

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37. https://doi.org/10.1038/s41581-019-0244-2.CrossRef

Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in US adults: an analysis of national data. JAMA Cardiol. 2018;3:572–81. https://doi.org/10.1001/jamacardio.2018.1240.CrossRef

Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, Wang J, Zhu M, Weintraub WS, Gao R, China Hypertension Survey I. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137:2344–56. https://doi.org/10.1161/CIRCULATIONAHA.117.032380.CrossRef

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9. https://doi.org/10.1016/j.jhep.2020.03.039.CrossRef

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8. https://doi.org/10.1136/bmj.39335.541782.AD.CrossRef

Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, Persu A, Mancia G, Kreutz R, European Society of Hypertension C, the European Society of Hypertension Working Group on Blood Pressure M, Cardiovascular V. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39:1293–302. https://doi.org/10.1097/HJH.0000000000002843.CrossRef

Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, Group ESCSD. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339.CrossRef

Niiranen TJ, Kalesan B, Mitchell GF, Vasan RS. Relative contributions of pulse pressure and arterial stiffness to cardiovascular disease. Hypertension. 2019;73:712–7. https://doi.org/10.1161/HYPERTENSIONAHA.118.12289.CrossRef

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.CrossRef

10.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. https://doi.org/10.1007/BF00280883.CrossRef

11.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10. https://doi.org/10.1210/jcem.85.7.6661.CrossRef

12.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.CrossRef

13.

Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97. https://doi.org/10.1001/jama.285.19.2486

14.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https://doi.org/10.1186/1471-230X-6-33.CrossRef

15.

Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47:458–72. https://doi.org/10.1002/bimj.200410135.CrossRef

16.

Theofilis P, Vordoni A, Kalaitzidis RG. Metabolic dysfunction-associated fatty liver disease in the National Health and Nutrition Examination Survey 2017–2020: epidemiology, clinical correlates, and the role of diagnostic scores. Metabolites. 2022;12:1070.CrossRef

17.

Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol. 2022;28:5691–706.CrossRef

18.

Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-328224.CrossRef

19.

Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, Kim SU, Lee JI. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67:4919–28. https://doi.org/10.1007/s10620-022-07508-6.CrossRef

20.

Tanaka M, Mori K, Takahashi S, Higashiura Y, Ohnishi H, Hanawa N, Furuhashi M. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than does fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant. 2022. https://doi.org/10.1093/ndt/gfac188.CrossRef

21.

Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A Meta-analysis and systematic review of 12,620,736 Individuals. Endocr Pract. 2022;28:667–72. https://doi.org/10.1016/j.eprac.2022.03.016.CrossRef

22.

Morishita A, Tadokoro T, Fujihara S, Iwama H, Oura K, Fujita K, Tani J, Takuma K, Nakahara M, Shi T, Haba R, Okano K, Nishiyama A, Ono M, Himoto T, Masaki T. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. PLoS ONE. 2022;17:e0261310. https://doi.org/10.1371/journal.pone.0261310.CrossRef

23.

Akuta N, Kawamura Y, Fujiyama S, Saito S, Muraishi N, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study. Hepatol Commun. 2022;6:2286–97. https://doi.org/10.1002/hep4.2005.CrossRef

24.

Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6:120–32. https://doi.org/10.1002/hep4.1696.CrossRef

25.

Li X, Wu X, Jia Y, Fu J, Zhang L, Jiang T, Liu J, Wang G. Liraglutide decreases liver fat content and serum fibroblast growth factor 21 levels in newly diagnosed overweight patients with type 2 diabetes and nonalcoholic fatty liver disease. J Diabetes Res. 2021;2021:3715026. https://doi.org/10.1155/2021/3715026.CrossRef

26.

Morieri ML, Targher G, Lapolla A, D’Ambrosio M, Tadiotto F, Rigato M, Frison V, Paccagnella A, Simioni N, Avogaro A, Fadini GP. Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutr Metab Cardiovasc Dis. 2021;31:3474–83. https://doi.org/10.1016/j.numecd.2021.08.049.CrossRef

27.

Jianping W, Xuelian Z, Anjiang W, Haiying X. Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:586–93. https://doi.org/10.1097/MCG.0000000000001556.CrossRef

28.

Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M. Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis. Diabetes Metab Syndr. 2022;16:102539. https://doi.org/10.1016/j.dsx.2022.102539.CrossRef

29.

Saha M, Manna K, Das SK. Melatonin suppresses NLRP3 inflammasome activation via TLR4/NF-kappaB and P2X7R signaling in high-fat diet-induced murine NASH model. J Inflamm Res. 2022;15:3235–58. https://doi.org/10.2147/JIR.S343236.CrossRef

30.

Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The effects of melatonin in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Adv Biomed Res. 2017;6:40. https://doi.org/10.4103/2277-9175.204593.CrossRef

31.

Akhavan Rezayat A, Ghasemi Nour M, Bondarsahebi Y, Hozhabrossadati SA, Amirkhanlou F, Akhavan Rezayat S, Kiani M, Imani B. The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: a systematic review and Meta-analysis on clinical trial studies. Eur J Pharmacol. 2021;905:174154. https://doi.org/10.1016/j.ejphar.2021.174154.CrossRef

32.

Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573–82. https://doi.org/10.1016/j.cgh.2021.02.030.CrossRef

33.

Ruiz-Manriquez J, Olivas-Martinez A, Chávez-García LC, Fernández-Ramírez A, Moctezuma-Velazquez C, Kauffman-Ortega E, Castro-Narro G, Astudillo-García F, Escalona-Nandez I, Aguilar-Salinas CA, Navarro-Alvarez N, Torre A. Prevalence of metabolic-associated fatty liver disease in Mexico and development of a screening tool: the MAFLD-S score. Gastro Hep Adv. 2022;1:352–8. https://doi.org/10.1016/j.gastha.2021.12.011.CrossRef

34.

Theofilis P, Vordoni A, Nakas N, Kalaitzidis RG. Endothelial dysfunction in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Life (Basel). 2022;12:718. https://doi.org/10.3390/life12050718.CrossRef

35.

Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613. https://doi.org/10.1155/2018/9547613.CrossRef

36.

Tan X, Liu Y, Long J, Chen S, Liao G, Wu S, Li C, Wang L, Ling W, Zhu H. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease. Mol Nutr Food Res. 2019;63:e1900257. https://doi.org/10.1002/mnfr.201900257.CrossRef

37.

Rodrigo R, Gonzalez J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res. 2011;34:431–40. https://doi.org/10.1038/hr.2010.264.CrossRef

38.

Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis C, Tousoulis D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9:781. https://doi.org/10.3390/biomedicines9070781.CrossRef

39.

Avery EG, Bartolomaeus H, Maifeld A, Marko L, Wiig H, Wilck N, Rosshart SP, Forslund SK, Muller DN. The gut microbiome in hypertension: recent advances and future perspectives. Circ Res. 2021;128:934–50. https://doi.org/10.1161/CIRCRESAHA.121.318065.CrossRef

40.

Oikonomou E, Leopoulou M, Theofilis P, Antonopoulos AS, Siasos G, Latsios G, Mystakidi VC, Antoniades C, Tousoulis D. A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications. Atherosclerosis. 2020;309:16–26. https://doi.org/10.1016/j.atherosclerosis.2020.07.027.CrossRef

41.

Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021;22:11170. https://doi.org/10.3390/ijms222011170.CrossRef

42.

Sagris M, Theofilis P, Antonopoulos AS, Oikonomou E, Paschaliori C, Galiatsatos N, Tsioufis K, Tousoulis D. Inflammation in coronary microvascular dysfunction. Int J Mol Sci. 2021;22:13471. https://doi.org/10.3390/ijms222413471.CrossRef

43.

Sagris M, Theofilis P, Antonopoulos AS, Tsioufis C, Oikonomou E, Antoniades C, Crea F, Kaski JC, Tousoulis D. Inflammatory mechanisms in COVID-19 and atherosclerosis: current pharmaceutical perspectives. Int J Mol Sci. 2021;22:6607. https://doi.org/10.3390/ijms22126607.CrossRef

44.

Suarez-Ortegon MF, McLachlan S, Fernandez-Real JM, Tuomainen TP, Aregbesola A, Wild SH. Serum ferritin and incident cardiometabolic diseases in Scottish adults. Cardiovasc Diabetol. 2022;21:26. https://doi.org/10.1186/s12933-022-01450-7.CrossRef

45.

Kang HT, Linton JA, Kwon SK, Park BJ, Lee JH. Ferritin level is positively associated with chronic kidney disease in Korean men, based on the 2010–2012 Korean National Health and Nutrition Examination Survey. Int J Environ Res Public Health. 2016. https://doi.org/10.3390/ijerph13111058.CrossRef

46.

Wu YH, Wang SY, Li MX, He H, Yin WJ, Guo YH, Zhang HQ, Sun ZM, Zhang D, Wang X, Sun SY, Tang SX, Du R, Zhang CH. Serum ferritin independently predicts the incidence of chronic kidney disease in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:99–105. https://doi.org/10.2147/DMSO.S228335.CrossRef

47.

Fibrinogen Studies C, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D’Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–809. https://doi.org/10.1001/jama.294.14.1799.CrossRef

48.

Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. https://doi.org/10.1056/NEJMoa1107477.CrossRef

49.

Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92. https://doi.org/10.1161/01.cir.0000042700.48769.59.CrossRef

50.

Goicoechea M, de Vinuesa SG, Gomez-Campdera F, Aragoncillo I, Verdalles U, Mosse A, Luno J. Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl. 2008. https://doi.org/10.1038/ki.2008.519.CrossRef

51.

Huang MJ, Wei RB, Wang Y, Su TY, Di P, Li QP, Yang X, Li P, Chen XM. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open. 2017;7:e014294. https://doi.org/10.1136/bmjopen-2016-014294.CrossRef

52.

Hagstrom E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG, Investigators OO. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab. Circulation. 2022;146:657–72. https://doi.org/10.1161/CIRCULATIONAHA.121.057807.CrossRef

53.

Walldius G, de Faire U, Alfredsson L, Leander K, Westerholm P, Malmstrom H, Ivert T, Hammar N. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: a cohort study. PLoS Med. 2021;18:e1003853. https://doi.org/10.1371/journal.pmed.1003853.CrossRef

54.

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022. https://doi.org/10.1093/eurheartj/ehac361.CrossRef

55.

Goek ON, Kottgen A, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012;27:2839–47. https://doi.org/10.1093/ndt/gfr795.CrossRef

56.

Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59:577–85. https://doi.org/10.1194/jlr.R083626.CrossRef

57.

Sofat R, Cooper JA, Kumari M, Casas JP, Mitchell JP, Acharya J, Thom S, Hughes AD, Humphries SE, Hingorani AD. Circulating apolipoprotein E concentration and cardiovascular disease risk: meta-analysis of results from three studies. PLoS Med. 2016;13:e1002146. https://doi.org/10.1371/journal.pmed.1002146.CrossRef

58.

Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, Borghi C. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8:11529. https://doi.org/10.1038/s41598-018-29955-w.CrossRef

59.

Pugliese NR, Mengozzi A, Virdis A, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell’Oro R, Bruno B, Lippa L, D’Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Masi S, Borghi C, Working Group on Uric A, Cardiovascular Risk of the Italian Society of H. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clin Res Cardiol. 2021;110:1073–82. https://doi.org/10.1007/s00392-021-01815-0.CrossRef

60.

Theofilis P, Tsimihodimos V, Vordoni A, Kalaitzidis RG. Serum uric acid levels and cardiometabolic profile in middle-aged, treatment-naive hypertensive patients. High Blood Press Cardiovasc Prev. 2022;29:367–74. https://doi.org/10.1007/s40292-022-00522-9.CrossRef

61.

Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell’Oro R, Bruno B, Lippa L, D’Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Borghi C, from the Working Group on Uric A, Cardiovascular Risk of the Italian Society of H. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75:302–8. https://doi.org/10.1161/HYPERTENSIONAHA.119.13643.CrossRef

62.

Son YB, Yang JH, Kim MG, Jo SK, Cho WY, Oh SW. The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: a health checkup cohort study. PLoS ONE. 2021;16:e0244106. https://doi.org/10.1371/journal.pone.0244106.CrossRef

63.

Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71:362–70. https://doi.org/10.1053/j.ajkd.2017.08.017.CrossRef

64.

Yu H, Zhao L, Liu L, Li Y, Sun J, Liu Y. Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients. Medicine (Baltimore). 2021;100:e26946. https://doi.org/10.1097/MD.0000000000026946.CrossRef

65.

Bao T, Ying Z, Gong L, Du J, Ji G, Li Z, Gao W, Jiang X, Yang H, Huang Y, Tang H. Association between serum uric acid and nonalcoholic fatty liver disease in nonobese postmenopausal women: a cross-sectional study. Sci Rep. 2020;10:10072. https://doi.org/10.1038/s41598-020-66931-9.CrossRef

66.

Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, Ma J, Feng S, Li WD. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179. https://doi.org/10.3389/fendo.2020.00179.CrossRef

67.

Oral A, Sahin T, Turker F, Kocak E. Relationship between serum uric acid levels and nonalcoholic fatty liver disease in non-obese patients. Medicina (Kaunas). 2019. https://doi.org/10.3390/medicina55090600.CrossRef

68.

Xing Y, Chen J, Liu J, Song G, Ma H. Relationship between serum uric acid-to-creatinine ratio and the risk of metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:257–67. https://doi.org/10.2147/DMSO.S350468.CrossRef

69.

Titel: Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers
verfasst von: Panagiotis Theofilis
Aikaterini Vordoni
Vasilis Tsimihodimos
Rigas G. Kalaitzidis
Publikationsdatum: 01.01.2023
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 1/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-023-00558-5

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers

Abstract

Introduction

Aims

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Subclinical Hypertension-Mediated Organ Damage (HMOD) in Hypertension: Atherosclerotic Cardiovascular Disease (ASCVD) and Calcium Score

Elabela Peptide: A New Player in Hypertension and Vascular Damage

A Novel Peptide Elabela is Associated with Hypertension-Related Subclinical Atherosclerosis

Altered baroreflex sensitivity at rest and during Valsalva maneuver in healthy male offspring of hypertensive patients

Circadian Variations in Sympathetic Vasoconstriction in Older Adults with and Without Type 2 Diabetes

Commentary on: “HOMA-IR as a Predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-Analysis” by González-González JG et al. High Blood Pressure & Cardiovascular Prevention

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie